145 related articles for article (PubMed ID: 32455475)
1. COVID-19 in a melanoma patient under treatment with checkpoint inhibition.
Schmidle P; Biedermann T; Posch C
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e465-e466. PubMed ID: 32455475
[No Abstract] [Full Text] [Related]
2. Pyrexia by COVID-19 in a patient treated with dabrafenib/trametinib therapy.
Hashimoto H; Ito T; Ide T; Sasaki N; Hikichi S; Furue M
J Dermatol; 2021 Feb; 48(2):e122-e123. PubMed ID: 33200424
[No Abstract] [Full Text] [Related]
3. Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.
Pala L; Conforti F; Cocorocchio E; Ferrucci P; De Pas MT; Stucchi S; Repetto M; Saponara M; Queirolo P
Cancer Invest; 2021 Jan; 39(1):9-14. PubMed ID: 33125301
[TBL] [Abstract][Full Text] [Related]
4. The best treatments to use after checkpoint inhibition in melanoma.
McArthur G
Clin Adv Hematol Oncol; 2017 Apr; 15(4):242-245. PubMed ID: 28591097
[No Abstract] [Full Text] [Related]
5. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
[No Abstract] [Full Text] [Related]
6. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
7. Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment.
Serra-García L; Bosch-Amate X; Alamon-Reig F; Giavedoni P; Fuertes I; Morgado-Carrasco D; Iglesias P; Puig S; Mascaró JM
Int J Dermatol; 2021 Jan; 60(1):e30-e32. PubMed ID: 33040324
[No Abstract] [Full Text] [Related]
8. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
Russo I; Filoni A; Alaibac M
Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
[No Abstract] [Full Text] [Related]
9. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
10. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
[No Abstract] [Full Text] [Related]
11. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
[No Abstract] [Full Text] [Related]
12. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.
Lee B; Wong A; Kee D; Neeson P; Shackleton M; McArthur G; Sandhu S
Ann Oncol; 2016 Jun; 27(6):1174-1177. PubMed ID: 26861600
[No Abstract] [Full Text] [Related]
13. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
14. [Relationship between prior antibiotic treatment and response to immune checkpoint inhibitor therapy and survival in patients with cancer].
Bauereiß A; Wilhelm M
Strahlenther Onkol; 2020 May; 196(5):486-487. PubMed ID: 32166450
[No Abstract] [Full Text] [Related]
15. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
16. Durable response after cessation of anti-programmed death 1 therapy in four melanoma patients.
Handa T; Kato J; Sumikawa Y; Hida T; Horimoto K; Sato S; Sawada M; Fujioka M; Minowa T; Matsui Y; Uhara H
J Dermatol; 2019 Dec; 46(12):e461-e462. PubMed ID: 31583754
[No Abstract] [Full Text] [Related]
17. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report.
Yamamura K; Otsuka A; Kaku Y; Seidel JA; Nomura M; Nagai H; Matsumoto S; Kabashima K
J Dermatol; 2017 May; 44(5):547-548. PubMed ID: 27461159
[No Abstract] [Full Text] [Related]
18. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
19. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
[No Abstract] [Full Text] [Related]
20. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
